Dr. Lisa Danzig is founder and Chief Executive Officer of TROVANDO, Inc, a specialty genomics company focused on pathogen detection and seeing the unknown. Formerly Chief Medical Officer at Excision BioTherapeutics, a gene-therapy company in San Francisco, and Chief Medical Officer at PaxVax, a specialty vaccine company in Redwood City, California, she is a member of the Pandefense Advisory Group and is co-founder and managing partner of Amicitiam Partners.

While at Novartis she held global leadership roles within both the blood screening diagnostics and vaccines business units, and contributed to the development of meningococcal vaccines (Menjugate®, Menveo® and Bexsero®) as well as expedited development of pandemic influenza vaccines, living and working in Siena, Italy, Cambridge, MA, Hangzhou, China, and Emeryville, CA. During her tenure as an Epidemic Intelligence Service (EIS)officer with the U.S. CDC, she investigated outbreaks of healthcare associated infections with multi-drug resistant pathogens and taught epidemiology in Côte d’Ivoire to district health officers in West Africa. Dr. Danzig received her medical degree from Oregon Health Sciences University and completed residency and fellowship training in Internal Medicine and Infectious Diseases in San Francisco. She is an independent director at OrSense, and serves on the boards of the Sustainable Sciences Institute, the Karuna Foundation, the Bhutan Foundation, as well as an advisor to the Lemelson Foundation. Dr. Danzig received Peru’s “Order of Merit for Distinguished Services” at the rank of Grand Official from President Francisco Sagasti in July 2021 for contributions that enabled effective vaccine procurement. Dr. Danzig also served as an advisor to the pandemic response in Bhutan.

Upcoming Events

Note: Speaker biographies were written at time of speaking engagement and may not reflect their current job title and position.
View All
Connect With Dr.